UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-09 ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q2 2023 Results Conference Call August 2, 2023 4:30 PM ET Company Participants Karina Calzadilla - Head, IR Chad Robins - CEO and Co-founder Tycho Peterson - CFO Nitin Sood - Chief Commercial Officer, MRD Harlan Robins - Chief Scientific Officer and Co-founder Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Rachel Vatnsdal - JPMorgan Chase Dan Brennan - TD Cowen David Westenberg - Piper Sandler Mark Massaro - BTIG Eli ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____to _____ Commission File Number: 001-38957 ADAPTIVE BIOTECHNOLOGIES CORPORATION (Exact Name of Registrant as Specified in its Charter) Washington 27-0907024 ...

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants Karina Calzadilla - Vice President of Investor Relations Chad Robins - Co-founder, Chairman & Chief Executive Officer Tycho Peterson - Chief Financial Officer Nitin Sood - Chief Commercial Officer, MRD Sharon Benzeno - Chief Commercial Officer, Immune Medicine Conference Call Participants Mark Massaro - BTIG David Westenberg - Piper Sandler Derik De Bruin - Bank of America Yuko Oku ...

Financial Performance - Revenue for Q1 2023 was $37,647,000, a decrease of 2.5% compared to $38,620,000 in Q1 2022[10] - Total operating expenses for Q1 2023 were $94,840,000, down from $101,687,000 in Q1 2022, representing a reduction of approximately 6.7%[10] - Net loss for Q1 2023 was $57,700,000, compared to a net loss of $62,796,000 in Q1 2022, indicating an improvement of about 8.4%[10] - The company reported a comprehensive loss of $55,489,000 for Q1 2023, an improvement from a comprehensive loss of $66,442,000 in Q1 2022[12] - Net loss for the three months ended March 31, 2023, was $57.7 million, an improvement from a net loss of $62.8 million for the same period in 2022, representing a decrease of approximately 3.5%[16] - The net loss attributable to the company for the three months ended March 31, 2023, was $57.699 million, compared to a net loss of $62.736 million for the same period in 2022, indicating a reduction in loss of approximately 8%[76] - Adjusted EBITDA for the three months ended March 31, 2023, was $(37,098,000), an improvement from $(43,078,000) in the same period of 2022[102] Cash and Assets - Cash and cash equivalents increased to $94,612,000 as of March 31, 2023, up from $90,030,000 at the end of 2022[8] - Total assets decreased to $791,463,000 as of March 31, 2023, down from $856,617,000 at the end of 2022, reflecting a decline of approximately 7.6%[8] - Cash, cash equivalents, and restricted cash at the end of the period were $96.9 million, down from $117.2 million at the end of March 31, 2022, indicating a decrease of approximately 17.3%[16] - As of March 31, 2023, the company had cash, cash equivalents, and marketable securities totaling $440.7 million, down from $498.2 million as of December 31, 2022[80] Revenue Breakdown - Revenue from significant customers included Genentech, Inc. and Roche Group, contributing 26.6% of total revenue for the three months ended March 31, 2023, compared to 33.8% in the same period of 2022[25] - Immune Medicine revenue for Q1 2023 was $16.220 million, down 22.8% from $20.816 million in Q1 2022[29] - MRD service revenue increased significantly to $21.427 million in Q1 2023, compared to $14.804 million in Q1 2022, representing a growth of 44.7%[29] - The company recognized $9.1 million in collaboration revenue from the Genentech Agreement in Q1 2023, down from $12.3 million in Q1 2022[33] - Immune Medicine revenue decreased by $4,596,000, or 22%, primarily due to a $3,200,000 decrease from the Genentech Agreement and a $1,000,000 decrease from biopharmaceutical customers[93] - MRD revenue increased by $3,623,000, or 20%, driven by a $4,000,000 increase from clonoSEQ services and a $1,500,000 increase from MRD sample testing services[93] Expenses - Research and development expenses for Q1 2023 were $32,601,000, down from $37,839,000 in Q1 2022, a decrease of approximately 13.8%[10] - Research and development expenses decreased by $5,238,000, or 14%, mainly due to reduced investments in T-Detect and TCRAntigen Map development[95] - Sales and marketing expenses decreased by $3,785,000, or 15%, primarily due to lower personnel and marketing costs[98] - General and administrative expenses decreased by $3,313,000, or 14%, largely due to reduced building and facility-related expenses[99] - The company’s share-based compensation expense increased to $14.7 million for the three months ended March 31, 2023, compared to $12.9 million for the same period in 2022, reflecting an increase of approximately 14%[16] Future Outlook - The company expects revenue to increase over the long term, although fluctuations may occur due to the uncertain nature of product delivery and customer decisions[81] - The company expects revenue from current and future products and services to grow over the long term, despite potential near-term variability[104] - The company plans to utilize existing cash primarily for research and development initiatives, marketing activities, and streamlining laboratory operations[104] - The company is focused on expanding revenue in two growth areas: IM Pharma Services and Drug Discovery, leveraging its proprietary technologies[80] Liabilities and Agreements - Current liabilities decreased to $90,101,000 as of March 31, 2023, compared to $109,788,000 at the end of 2022, a reduction of about 18%[8] - The revenue interest liability increased from $125.360 million at December 31, 2022, to $127.008 million by March 31, 2023, with interest expense of $3.531 million recorded[49] - The company has a collaboration agreement with Genentech, which is a significant component of its revenue generation strategy[81] - The company has a responsibility to enter into a supply and manufacturing agreement for patient-specific TCRs related to Personalized Product therapies, which is contingent on Genentech's commercialization decisions[32] Stock and Equity - As of March 31, 2023, the company had reserved a total of 44,794,592 shares of common stock for future issuance under various equity incentive plans[54] - The company had 14,783,332 stock options outstanding with a weighted average exercise price of $15.97[61] - The total share-based compensation expense for the three months ended March 31, 2023, was $14.671 million, compared to $12.861 million for the same period in 2022, representing an increase of approximately 14%[71] - The weighted-average grant date fair value per share of stock options granted during the three months ended March 31, 2023, was $5.61, down from $7.81 in 2022[70] - The company granted 6,486,163 restricted stock units during the three months ended March 31, 2023, with 1,029,209 units vested during the same period[63]

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q4 2022 Earnings Conference Call February 14, 2023 4:30 PM ET Corporate Participants Karina Calzadilla - VP, Investor Relations Tycho Peterson - Chief Financial Officer Sharon Benzeno - Chief Commercial Officer, Immune Medicine Nitin Sood - Chief Commercial Officer, MRD Chad Robins - Co-founder, Chairman and Chief Executive Officer Conference Call Participants Derik De Bruin - Bank of America David Westenberg - Piper Sandler Daniel Brennan - Cowen Julia Che ...

Fourth Quarter and FY 2022 Earnings Conference Call This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer ...

Revenue Growth - Revenue increased by 20% to $185.3 million in 2022, with double-digit percentage increases in both MRD and IM business areas[16] - IM Pharma Services revenue increased by 67% from 2021, with over 85 partners and more than 140 active studies utilizing immune receptor data[19] - The company aims for revenue growth at a compound annual growth rate of 20% to 30% through 2027[16] clonoSEQ Performance - clonoSEQ test volume grew by 51% to 36,871 tests delivered, with unique patients tested increasing by 53% to over 33,000[17] - clonoSEQ has received Medicare coverage for over 245 million covered lives for ALL and MM, over 190 million for CLL, and over 70 million for DLBCL[24] - clonoSEQ testing has been ordered for over 33,000 unique patients and is utilized by more than 60 biopharmaceutical companies in 187 active clinical trials, representing approximately 21% penetration in lymphoid cancers[24] Market Opportunities - The estimated global market opportunity for the immune medicine portfolio is approximately $49 billion, including $5 billion for MRD and $44 billion for IM[15] - The company aims to deepen penetration of clonoSEQ by increasing blood-based testing and expanding into new patient populations within NHL, starting with DLBCL[25] Financial Outlook - The company expects positive adjusted EBITDA by the end of 2025 and cash flow breakeven by the end of 2026[16] - The company has $498.2 million in cash, cash equivalents, and marketable securities as of December 31, 2022, with a goal of achieving positive adjusted EBITDA by the end of 2025[42] Partnerships and Collaborations - The partnership with Genentech has advanced TCR cellular therapies in oncology, with three TCR fully characterized data packages delivered[19] - The partnership with Genentech aims to develop TCR therapeutics for oncology, with progress made on both shared and personalized product pathways[41] - The company has transferred clonoSEQ technology to seven labs across multiple countries, including France, Germany, and Japan, to provide local testing options[66] Technology and Innovation - The clonoSEQ assay is the first and only MRD test to receive Medicare coverage for DLBCL patients[17] - The MIRA technology allows for the identification of TCRs specific to thousands of antigens simultaneously, significantly enhancing sensitivity compared to standard techniques[58] - The company has identified and characterized over 5,000 unique antigen-specific TCRs against 600 different clinically relevant targets, forming a pipeline of potential clinical candidates[60] Regulatory and Compliance - The company holds necessary federal and state licenses, including CLIA certification, to operate clinical laboratories[136] - The company must comply with various federal, state, and local regulations regarding the handling and disposal of medical waste, which adds complexity to operations[148] - The company’s compliance program is designed to prevent and detect violations of law, incorporating principles from the AdvaMed Code of Ethics and HHS OIG guidelines[154] Employee and Corporate Culture - The entrepreneurial and data-driven corporate culture includes a team of 147 professionals with medical or doctoral degrees, enhancing the company's capabilities in drug discovery and commercialization[45] - As of December 31, 2022, the company had 790 full-time employees, with 147 holding medical or doctoral degrees[99] Intellectual Property - The company has filed 799 patent applications, with 470 issued, covering improvements in sequencing methods and adaptive immune receptor applications[44] - The intellectual property portfolio includes 799 patent applications filed worldwide since 2009 and 429 issued patents across the immune medicine platform[113] Clinical Trials and Studies - A retrospective cohort analysis showed that MRD status influenced treatment decisions for 67 out of 400 newly diagnosed myeloma patients, indicating the potential for MRD to modify treatment[27] - The Watch Registry, a clinical registry launched in 2020, aims to enroll approximately 500 patients with lymphoid malignancies, with over 400 patients enrolled to date[66] Financial Agreements - The company received a $300 million upfront payment from Genentech and may receive up to $1.8 billion in total, including milestone payments[104] - Under the Revenue Interest Purchase Agreement, the company received $124.4 million in September 2022 and may receive up to an additional $125 million by September 2025[108]